Ultra-low dose rituximab as add-on therapy in anti-MDA5-positive patients with polymyositis /dermatomyositis associated ILD

To evaluate the efficacy and safety of ultra-low dose (100  mg) rituximab (RTX) administration in anti-melanoma differentiation-associated gene 5 (MDA5) positive patients with polymyositis/dermatomyositis (PM/DM) associated interstitial lung disease.

Source: Respiratory Medicine - May 14, 2020 Category: Respiratory Medicine Authors: Meng-meng Mao, Shu Xia, Bing-peng Guo, Wei-ping Qian, Ze-xuan Zheng, Xiao-min Peng, Rong-chang Chen, Qun Luo, Qian Han Source Type: research